Indikation:	Studientitel:	Leiter klinische Prüfung:	Ansprechpartner:
Myelom Erstdiagnose	**GMMG – HD 6:** A randomized phase III trial on the effect of elotuzumab in VRD induction / consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. **Rekrutierung abgeschlossen!**	Prof. Dr. med. Hartmut Goldschmid, Heidelberg	Prof. Dr. med. Katja Weisel, Tübingen
Hochrisiko Myelom Erstdiagnose	**GMMG-CONCEPT:** Eine klinische Phase II Studie zur Induktions-, Konsolidierungs- und Erhaltungstherapie mit Isatuximab, Carfilzomib, Lenalidomid und Dexamethason (I-KRd) in der Primärtherapie des Hochrisikomyeloms.	Prof. Dr. med. Katja Weisel, Tübingen	Prof. Dr. med. Katja Weisel, Tübingen
Myelom Erstdiagnose + Rezidiv	**NSMM 5001 Insight**: Eine internationale, prospektive, nicht-interventionelle Beobachtungsstudie zur Ausprägung, zu Behandlungsmustern und Ergebnissen bei Patienten mit multiplem Myelom.	Prof. Dr. med. Hartmut Goldschmidt, Heidelberg	Prof. Dr. med. Katja Weisel, Tübingen
Myelom Rezidiv	**CA 204-125:** An open-label randomized Phase 2 Trial of Pomalidomide / Dexamethasone with or without Elotuzumab in relapsed and refractory Multiple Myeloma. **Rekrutierung abgeschlossen!**	Dr. med. Marc Raab, Heidelberg	Prof. Dr. med. Katja Weisel, Tübingen
Myelom Rezidiv	**MM007:** A Phase 3 multicenter randomized open-label Study to compare the efficacy and safety of Pomalidomide, Bortezomib and low-dose Dexamethasone vs Bortezomib and low-dose Dexamethasone in Subjects with relapsed or refractory Multiple Myeloma. **Rekrutierung abgeschlossen!**	Prof. Dr. med. Katja Weisel, Tübingen	Prof. Dr. med. Katja Weisel, Tübingen
Myelom Rezidiv	**Medi 4736 MM001:** A Phase 1b multicentre open-label study to determine the recommended dose and	Prof. Dr.med. Katja Weisel, Tübingen	Prof. Dr. med. Katja Weisel, Tübingen

	regimen of Durvalumab either as monotherapy or in combination with Pomalidomide with or without low-dose Dexamethasone in subjects with relapsed and refractory Multiple Myeloma. **Rekrutierung abgeschlossen!**.		
Myelom Rezidiv	**Medi 4736-MM003:** A Phase 2 multicenter open-label study to determine the safety and efficacy for the combination of Durvalumab and Daratumumab in Subjects with relapsed and refractory Multiple Myeloma. **Rekrutierung abgeschlossen!**	Prof. Dr. med. Katja Weisel, Tübingen	Prof. Dr. med. Katja Weisel, Tübingen
Myelom Rezidiv	**BIRMA:** LGX818 in combination with MEK162 in refractory or relapsed Multiple Myeloma patients with BRAFV600E or BRAFV600K mutation.	Prof. Dr. med. Hartmut Goldschmidt, Heidelberg	Prof. Dr. med. Katja Weisel, Tübingen
Myelom Rezidiv	**DANTE:** Eine multizentrische Phase II Studie**.** Daratumumab in Kombination mit Bortezomib und Dexamethasone bei Patienten mit rezidiviertem oder rezidiviertem und refraktärem Multiplen Myelom und hochgradiger Nierenfunktionseinschränkung einschließlich Patienten unter Hämodialyse.	Prof. Dr.med. Katja Weisel, Tübingen	Prof. Dr. med. Katja Weisel, Tübingen
Myelom Rezidiv	**AGMT_MM-1 / EMN-13:** Ixazomib in Combination with Thalidomide – Dexamethasone in patients with relapsed and/or refractory Multiple Myeloma. **Rekrutierung abeschlossen!**	Prof. Dr. med. Heinz Ludwig, Wien	Prof. Dr. med. Katja Weisel, Tübingen
Myelom Rezidiv	**Roche BO 39813:** A Phase IB/II Study of Cobimetinib administered as single Agent and in combination with Venetoclax, with or without Atezolizumab, in Patients with relapsed and refractory Multiple Myeloma.	Prof. Dr. med. Hartmut Goldschmidt, Heidelberg	Prof. Dr. med. Katja Weisel, Tübingen

Myelom Rezidiv	**Karyopharm STORM:** A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients with Multiple Myeloma Previously Treated with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and Daratumumab, and Refractory to Prior Treatment with Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and the anti-CD38 mAb Daratumumab. **Rekrutierung abgeschlossen!**	Prof. Dr. med. Monika Engelhardt, Freiburg	Prof. Dr. med. Katja Weisel, Tübingen
Myelom Rezidiv	**C16029:** A Phase 2/3, randomized, open-label Study comparing oral Ixazomib / Dexamethasone and oral Pomalidomide / Dexamethasone in relapsed and / or refractory Multiple Myeloma.	Prof. Dr. med. Katja Weisel Tübingen	Prof. Dr. med. Katja Weisel, Tübingen
Myelom Rezidiv	**IMROZ EFC 12522:** A Phase 3 randomized, open-label, multicenter study assessing the clinical benefit of Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone in Patients with newly diagnosed Multiple Myeloma not eligible for transplant. **Rekrutierung abgeschlossen!**	Prof.Dr.med. Hartmut Goldschmidt Heidelberg	Prof. Dr. med. Katja Weisel Tübingen
Myelom Rezidiv	**GSK2857916:** A Phase 2, open-label, randomized, two-arm Study to Investigate the Efficacy and Safety of two doses of the Antibody Drug Conjugate GSK2857916 in Participants with Multiple Myeloma who had 3 or more prior Lines of Treatment, are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and have failed an Anti-CD38 Antibody. **Rekrutierung abgeschlossen!**	Prof. Dr. med. Katja Weisel, Tübingen	Prof. Dr. med. Katja Weisel, Tübingen
Myelom Rezidiv	**Aquila SMM3001:** A Phase 3 randomized, multicenter study of subcutaneous Daratumumab versus active monitoring in Subjects with high-risk Smoldering Multiple Myeloma.	Prof. Dr. med. Hartmut Goldschmidt, Heidelberg	Prof. Dr. med. Katja Weisel Tübingen

Myelom Rezidiv	**BB2121-MM001:** A Phase 2, Multicenter Study to determine the efficacy of BB2121 in Subjects with relapsed / refractory Multiple Myeloma. **Rekrutierung abgeschlossen!**	Prof. Dr. med. Hermann Einsele	Prof. Dr. med. Katja Weisel, Tübingen
Myelom Rezidiv	**EMN Apollo:** A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.		Prof. Dr. med. Katja Weisel, Tübingen
Amyloidose Erstdiagnose	**54767414AMY3001:** A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis.		Prof. Dr. med. Katja Weisel, Tübingen
Myelom Erstdiagnose	**GMMG – HD7:** A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly diagnosed multiple myeloma.		Prof. Dr. med. Katja Weisel, Tübingen